US2010016356A1PendingUtilityA1

Method for treating thrombosis and inhibiting platelet aggregation with 21-(s)-argatroban

45
Assignee: TIANJIN WEIJIE TECHNOLOGY CO LPriority: Apr 13, 2007Filed: Sep 24, 2009Published: Jan 21, 2010
Est. expiryApr 13, 2027(~0.7 yrs left)· nominal 20-yr term from priority
Inventors:Honghai Song
A61P 7/02A61K 31/4709
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for inhibiting coagulation including administering to a patient in need thereof a pharmaceutical composition having 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for inhibiting coagulation having 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof. Compared with 21 (R) Argatroban, 21-(S)-Argatroban significantly prolongs coagulation time of whole blood (CT), recalcification time (RT), kaolin partial thromboplastin time (APTT), pro-time prothrombin time (PT), thrombin time (TT), and reduces platelet adhesion rate and platelet aggregation rate in healthy dogs. Therefore, 21-(S)-Argatroban has a stronger effect of inhibiting coagulation and reducing therapeutically effective dose and is suitable for treatment and/or prevention of thrombosis and inhibiting platelet aggregation.

Claims

exact text as granted — not AI-modified
1 . A method for inhibiting coagulation comprising administering to a patient in need thereof a pharmaceutical composition comprising 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof. 
   
   
       2 . The method of  claim 1 , wherein said pharmaceutical composition further comprises an excipient. 
   
   
       3 . The method of  claim 1 , wherein said pharmaceutical composition further comprises 21(R) Argatroban and/or a pharmaceutically acceptable salt thereof. 
   
   
       4 . The method of  claim 3 , wherein said pharmaceutical composition further comprises an excipient. 
   
   
       5 . The method of  claim 3 , wherein a mole ratio of said 21-(S)-Argatroban to said 21(R) Argatroban is ≧70:30. 
   
   
       6 . The method of  claim 3 , wherein a mole ratio of said 21-(S)-Argatroban to said 21(R) Argatroban is ≧76:23. 
   
   
       7 . The method of  claim 3 , wherein a mole ratio of said 21-(S)-Argatroban to said 21(R) Argatroban is ≧93:7. 
   
   
       8 . The method of  claim 1 , wherein said inhibiting coagulation is the treatment and/or prevention of thrombosis. 
   
   
       9 . The method of  claim 1 , wherein said inhibiting coagulation is inhibiting platelet aggregation. 
   
   
       10 . A pharmaceutical composition comprising 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof. 
   
   
       11 . The composition of  claim 10  further comprises an excipient. 
   
   
       12 . The composition of  claim 10  further comprises 21(R) Argatroban and/or a pharmaceutically acceptable salt thereof. 
   
   
       13 . The composition of  claim 12  further comprises an excipient. 
   
   
       14 . The composition of  claim 12 , wherein a mole ratio of said 21-(S)-Argatroban to said 21(R) Argatroban is ≧70:30. 
   
   
       15 . The composition of  claim 12 , wherein a mole ratio of said 21-(S)-Argatroban to said 21(R) Argatroban is ≧76:23. 
   
   
       16 . The composition of  claim 12 , wherein a mole ratio of said 21-(S)-Argatroban to said 21(R) Argatroban is ≧93:7.

Join the waitlist — get patent alerts

Track US2010016356A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.